200 related articles for article (PubMed ID: 26057181)
21. Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.
Yuen KC; Koltowska-Häggström M; Cook DM; Fox JL; Jönsson PJ; Geffner ME; Abs R
Eur J Endocrinol; 2013 Oct; 169(4):511-9. PubMed ID: 23904277
[TBL] [Abstract][Full Text] [Related]
22. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.
Minniti G; Traish D; Ashley S; Gonsalves A; Brada M
Clin Endocrinol (Oxf); 2006 May; 64(5):542-8. PubMed ID: 16649974
[TBL] [Abstract][Full Text] [Related]
23. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours?
Hatrick AG; Boghalo P; Bingham JB; Ayres AB; Sonksen PH; Russell-Jones DL
Eur J Endocrinol; 2002 Jun; 146(6):807-11. PubMed ID: 12039701
[TBL] [Abstract][Full Text] [Related]
24. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up.
Olsson DS; Buchfelder M; Wiendieck K; Kremenevskaja N; Bengtsson BÅ; Jakobsson KE; Jarfelt M; Johannsson G; Nilsson AG
Eur J Endocrinol; 2012 Jun; 166(6):1061-8. PubMed ID: 22457235
[TBL] [Abstract][Full Text] [Related]
25. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
[TBL] [Abstract][Full Text] [Related]
26. The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke.
Jasim S; Alahdab F; Ahmed AT; Tamhane SU; Sharma A; Donegan D; Nippoldt TB; Murad MH
Endocrine; 2017 May; 56(2):267-278. PubMed ID: 27815769
[TBL] [Abstract][Full Text] [Related]
27. Growth hormone receptor expression and function in pituitary adenomas.
Clausen LR; Kristiansen MT; Rasmussen LM; Billestrup N; Blaabjerg O; Ledet T; Jørgensen JO
Clin Endocrinol (Oxf); 2004 May; 60(5):576-83. PubMed ID: 15104560
[TBL] [Abstract][Full Text] [Related]
28. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.
Losa M; Mortini P; Barzaghi R; Ribotto P; Terreni MR; Marzoli SB; Pieralli S; Giovanelli M
J Neurosurg; 2008 Mar; 108(3):525-32. PubMed ID: 18312100
[TBL] [Abstract][Full Text] [Related]
29. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
Chung TT; Drake WM; Evanson J; Walker D; Plowman PN; Chew SL; Grossman AB; Besser GM; Monson JP
Clin Endocrinol (Oxf); 2005 Sep; 63(3):274-9. PubMed ID: 16117814
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety of growth hormone replacement after CNS irradiation.
Mackenzie S; Craven T; Gattamaneni HR; Swindell R; Shalet SM; Brabant G
J Clin Endocrinol Metab; 2011 Sep; 96(9):2756-61. PubMed ID: 21715535
[TBL] [Abstract][Full Text] [Related]
31. Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Bunderen CC; van den Dries CJ; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Eur J Endocrinol; 2014 Aug; 171(2):151-60. PubMed ID: 24801587
[TBL] [Abstract][Full Text] [Related]
32. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
33. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence.
Arnold JR; Arnold DF; Marland A; Karavitaki N; Wass JA
Clin Endocrinol (Oxf); 2009 Mar; 70(3):435-8. PubMed ID: 19236640
[TBL] [Abstract][Full Text] [Related]
34. Clinical Characteristics and Postoperative Recovery of Hypopituitarism in Patients with Nonfunctional Pituitary Adenoma.
Zhang R; Wang Z; Gao L; Guo X; Feng C; Deng K; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
World Neurosurg; 2019 Jun; 126():e1183-e1189. PubMed ID: 30880207
[TBL] [Abstract][Full Text] [Related]
35. Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement.
Schneider HJ; Oertel H; Murck H; Pollmächer T; Stalla GK; Steiger A
Psychoneuroendocrinology; 2005 Jan; 30(1):29-37. PubMed ID: 15358440
[TBL] [Abstract][Full Text] [Related]
36. Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas: evidence for a better outcome independently of other patients' characteristics.
Losa M; Donofrio CA; Barzaghi R; Mortini P
Eur J Endocrinol; 2013 Dec; 169(6):735-42. PubMed ID: 23999643
[TBL] [Abstract][Full Text] [Related]
37. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
38. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas.
Webb SM; Rigla M; Wägner A; Oliver B; Bartumeus F
J Clin Endocrinol Metab; 1999 Oct; 84(10):3696-700. PubMed ID: 10523016
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.
Verweij T; Slagboom TNA; van Varsseveld NC; van der Lely AJ; Drent ML; van Bunderen CC
Eur J Endocrinol; 2021 Oct; 185(6):793-801. PubMed ID: 34605771
[TBL] [Abstract][Full Text] [Related]
40. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database.
Maiter D; Abs R; Johannsson G; Scanlon M; Jönsson PJ; Wilton P; Koltowska-Häggström M
Eur J Endocrinol; 2006 Aug; 155(2):253-60. PubMed ID: 16868138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
